"Omics" technologies and the immune system

Toxicology Mechanisms and Methods

Volumn 16, Issue 2-3, 2006, Pages 101-119

  Burns Naas, Leigh Ann ^a   Dearman, Rebecca J ^b   Germolec, Dori R ^c   Kaminski, Norbert E ^d   Kimber, Ian ^b   Ladics, Gregory S ^e   Luebke, Robert W ^f   Pfau, Jean C ^g   Pruett, Stephen B ^h  

^a PFIZER INC   (United States)

^b JEALOTT S HILL INTERNATIONAL RESEARCH CENTRE   (United Kingdom)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

^e DUPONT COMPANY   (United States)

^f U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^g UNIVERSITY OF MONTANA   (United States)

^h LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Allergy; Autoimmunity; Cytokines; Dendritic Cells; Dioxin; Ethanol; Gene Array; Hypersensitivity; Immune Mediated Disease; Immunomics; Immunopharmacogenomics Immunotoxicogenomics; Langerhan's Cell; Omics in Immunology; Omics in Immunotoxicology; TCDD

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; ABACAVIR; ALLOPURINOL; ALPHA INTERFERON; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA INTERFERON; CARBAMAZEPINE; COMPLEMENTARY DNA; CORTICOSTEROID; CXCL9 CHEMOKINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIETHYLSTILBESTROL; DNA; DRONABINOL; HEXACHLOROBENZENE; INSULIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHOTREXATE; PREDNISONE; SALBUTAMOL; TOLL LIKE RECEPTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ASTHMA; AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; BONE MARROW TOXICITY; CANCER SUSCEPTIBILITY; CHEMICAL TERATOGENESIS; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; DISEASE PREDISPOSITION; DNA MICROARRAY; DNA SEQUENCE; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EARLY RESPONSE GENE; ENVIRONMENTAL EXPOSURE; FETOTOXICITY; FLU LIKE SYNDROME; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SWITCHING; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOME ANALYSIS; GENOMICS; HAZARD ASSESSMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOCYTOTOXICITY; IMMUNOSURVEILLANCE; IMMUNOTOXICOGENOMIC; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR RECOGNITION; MULTIPLE SCLEROSIS; NONHUMAN; OCCUPATIONAL ALLERGY; PERITONEUM MACROPHAGE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RECEPTOR GENE; REVIEW; RHEUMATOID ARTHRITIS; SERIAL ANALYSIS OF GENE EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH2 CELL; THYMUS ATROPHY; TISSUE MICROARRAY; TISSUE SECTION; TOXICITY TESTING; UPREGULATION; XENOBIOTIC METABOLISM;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33645016082     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.1080/15376520600558424     Document Type: Review

References (164)

1. Aeby, P., Wyss, C., Beck, H., Griem, P., Scheffler, H., and Goebel, C. 2004. Characterization of the sensitizing potential of chemicals by in vitro analysis of dendritic cell activation and skin penetration. J. Invest. Dermatol. 122:1154-1164.
2. Ahmad, T., Tamboli, C. P., Jewell, D., and Colombel, J.-F. 2004. Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology 126:1533-1549.
3. Ahmed, S. S., and Tan, F. K. 2003. Identification of novel targets in scleroderma: Update on population studies, cDNA arrays, SNP analysis, and mutations. Curr. Opin. Rheumatol. 15:766-771.
4. Aiba, S., Terunuma, A. Manome, H., and Tagami, H. 1997. Dendritic cells differently respond to haptens and irritants by their production of cytokines and expression of co-stimulatory molecules. Eur. J. Immunol. 27:3031-3038.
5. Alexander, W. S., and Hilton, D. J. 2004. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu. Rev. Immunol. 22:503-529
6. Alexander, W. S., Starr, R., Fenner, J. E., Scott, C. L., Handman, E., Sprigg, N. S., Corbin, J. E., Cornish, A. L., Darwiche, R., Owczarek, C. M., Kay, T. W., Nicola, N. A., Hertzog, P. J., Metcalf, D., and Hilton, D. J. 1999. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98:597-608.
7. Antonopoulus, C., Cumberbatch, M., Dearman, R. J., Daniel, R. J., Kimber I., and Groves, R. W. 2001. Functional caspase-1 is required for Langerhans cell migration and optimal contact sensitization in mice. J. Immunol. 166:3672-3677.
8. Bateman, A., Belcourt, D., Bennett, H., Lazure, C., and Solomon, S. 1990. Granulins, a novel class of peptide from leukocytes. Biochem. Biophys. Res. Commun. 173:1161-1168.
9. Begovich, A. B., Carlton, V. E., Honigberg, L. A., Schrodi, S. J., Chokkalingam, A. P., Alexander, H. C., Ardlie, K. G., Huang, Q., Smith, A. M., Spoerke, J. M., Conn, M. T., Chang, M., Chang, S. Y., Saiki, R. K., Catanese, J. J., Leong, D. U., Garcia, V. E., McAllister, L. B., Jeffery, D. A., Lee, A. T., Batliwalla, F., Remmers, E., Criswell, L. A., Seldin, M. F., Kastner, D. L., Amos, C. I., Sninsky, J. J., and Gregersen, P. K. 2004. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am. J. Hum. Genet. 75:330-337.
10. Behrens, T. W., Graham, R. R., Kyogoku, C., Baechler, E. C., Ramos, P. S., Gillett, C., Bauer, J., Ortmann, W. A., Hippen, K. L., Peterson, E., Langefeld, C. D., Moser, K. L., Gaffney, P. M., and Gregersen, P. K. 2005. Progress towards understanding the genetic pathogenesis of systemic lupus erythematosus. Novartis Found Symp 267:145-60; discussion 160-164.
11. Bender, A., Sapp, M., Schuler, G., Steinmann, R. M., and Bhardwaj, N. 1996. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human peripheral blood. J. Immunol. Meth. 196:121-135.
12. Bilello, J. A. 2005. The agony and ecstasy of "OMIC" technologies in drug development. Curr. Molec. Med. 5:39-52.
13. Boldrick, J. C., Alizadeh, A. A., Diehn, M., Dudoit, S., Liu, C. L., Belcher, C. E., Botstein, D., Staudt, L. M., Brown, P. O., and Relman, D. A. 2002. Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc. Natl. Acad. Sci. USA. 99:972-977.
14. Boverhof, D. R., Tam, E., Harney, E., Crawford, A. S., Kaminski, R. B., N. E., and Zacharewski, T. R. 2004. 2,3,7,8-Tetrachlorodibenzo-p-dioxin induces suppressor of cytokine signaling 2 in murine B cells. Mol. Pharmacol. 66:1662-1670.
15. Brown, J. M., Archer, A. J., Pfau, J. C., and Holian, A. 2003. Silica accelerated systemic autoimmune disease in lupus-prone New Zealand mixed mice. Clin. Exp. Immunol. 131:415-421.
16. Brown, J. M., Schwanke, C. M., Pershouse, M. A., Pfau, J. C., and Holian, A. 2005. Effects of Rottlerin on Silica-Exacerbated Systemic Autoimmune Disease in New Zealand Mixed Mice. Am. J. Physiol. Lung Cell Mol. Physiol. Jul 22; [Epub ahead of print].
17. Brysha, M., Zhang, J. G., Bertolino, P., Corbin, J. E., Alexander, W. S., Nicola, N. A., Hilton, D. J., and Starr, R. 2001. Suppressor of cytokine signaling-1 attenuates the duration of interferon gamma signal transduction in vitro and in vivo. J. Biol. Chem. 276:22086-22089.
18. Burmester, G. R., and Haupl, T. 2004. Strategies using functional genomics in rheumatic diseases. Autoimmun. Rev. 3:541-549.
19. Cabral, G.A. and Dove Pettit, D. A. 1998. Drugs and immunity: Cannabinoids and their role in decreased resistance to infectious disease. J. Neuroimmunol. 83:116-123.
20. Camacho, I. A., Nagarkatti, M., and Nagarkatti, P. S. 2004. Evidence for induction of apoptosis in T cells from murine fetal thymus following perinatal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicol. Sci. 78:96-106.
21. Camacho, I. A., Singh, N., Hedge, V. L., Nagarkatti, M., and Nagarkatti, P. S. 2005. Treatment of mice with 2,3,7,8-tetrachlorodibenzo-p-dioxin leads to aryl hydrocarbon receptor-dependent nuclear translocation of NF-kappaB and expression of Fas ligand in thymic stromal cells and consequent apoptosis in T cells. J. Immunol. 175:90-103.
22. Casati., Aeby, P., Basketter, D. A., Cavani, A., Gennari, A., Gerberick, G. F., Griem, P., Hartung, T., Kimber, I., Lepoittevin, J.-P., Meade, B. J., Pallardy, M., Rougier, N., Rousset, F., Rubinstein, G., Sallusto, F., Verheyen, G. R., and Zuang, V. 2005. Dendritic cells as a tool for the predictive identification of skin sensitisation hazard. The report and recommendations of ECVAM workshop 51. ATLA 33:47-62.
23. Caux, C., Dezutter-Dambuyant, C., Schmitt, D., and Banchereau, J. 1992. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 360:258-261.
24. Chamaillard, M., Girardin, S. E., Viala, J., and Philpott, D. 2003. Nods, Nalps, and Naop: Intracellular regulators of bacterial-induced inflammation. Cell. Microbiol. 5:581-592.
25. Chaudhary, P. M., and Roninson, I. B. 1991. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66:85-94.
26. Chung, W. H., Hung, S. I., Hong, H. S., Hsih, M. S., Yang, L. C., Ho, H. C., Wu, J. Y., and Chen, Y. T. 2004. Nature 428:486.
27. Cooper, G. S., Miller, F. W., and Germolec, D. R. 2002. Occupational exposures and autoimmune diseases. Int. Immunopharmacol. 2:303-313.
28. Cox, A. L., Skipper, J., chen, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., and Slingluff, C. L., Jr. 1994. Identificaiton of a peptide recognized by five melanoma-specific human cytotoxic T-cell lines. Science 264:716-719.
29. Croker, B. P., Gilkeson, G., and Morel, L. 2003. Genetic interactions between susceptibility loci reveal epistatic pathogenic networks in murine lupus. Genes Immun. 4:575-585.
30. Crow, M. K., and Wohlgemuth, J. 2003. Microarray analysis of gene expression in lupus. Arthritis Res. Ther. 5:279-287.
31. Cumberbatch, M., Dearman, R. J., Griffiths, C. E. M., and Kimber, I. 2000. Langerhans cell migration. Clin. Exp. Detmatol. 25:413-418.
32. Cumberbatch, M., Dearman, R. J., and Kimber, I. 1997. Langerhans cells require signals from both tumour necrosis factor-α and interleukin 1β for migration. Immunology 92:388-395.
33. Daly, A. K, Day, C. P., and Donaldson, P. T. 2002. Polymorphisms in immunoregulatory genes. Towards individualized immunosuppressive therapy? Am. J. Pharmacogenomics 2:13-23.
34. Davies, N. J., Tadesse, M. G. T., Vannucci, M., Kikuchi, H., Trevino, V., Sarti, D., Dragoni, I., Contestabile, A., Zanders, E., and Falciani, F. 2004. Making sense of molecular signatures in the immune system. Comb. Chem High Throughput Screen 7:231-238.
35. D'Cruz, D. 2000. Autoimmune diseases associated with drugs, chemicals and environmental factors. Toxicol. Lett. 112-113:421-432.
36. De Groot, A. S. 2004. Immunome-derived vaccines. Expert Opin. Biol. Ther. 4:767-772.
37. De Groot, A. S., and Martin, W. 2003. From immunome to vaccine: Epitope mapping and vaccine design tools. Novartis Found. Symp. 254:57-72; discussion 72-6, 98-101, 250-252.
38. De Groot, A. S., and Rappuoli, R. 2004. Genome-derived vaccines. Expert Rev. Vaccines 3:59-76.
39. De Groot, A. S., Saint-Aubin, C., Bosma, A., Sbai, H., rayner, J., and Martin, W. 2001. Rapid determination of HLA B*07 ligands from the West Nile virus NY99 genome. Emerg. Infect. Dis. 7:706-13.
40. De Groot, A. S., Sbai, H., Aubin, C. S., McMurry, J., and Martin, W. 2002. Immuno-informatics: Mining genomes for vaccine components. Immunol. Cell Biol. 80:255-269.
41. De Groot, A. S., Marcon, L., Bishop, E. A., Rivera, D., Kutzler, M., Weiner, D., and Martin, W. 2005a. HIV vaccine development by computer assisted design: The GAIA vaccine. Vaccine 23:2136-2148.
42. De Groot, A. S., McMurry, J., Marcon, L., Franco, J., Rivera, D., Kutzler, M., Weiner, D., and Martin, B. 2005b. Developing an epitope-driven tuberculosis (TB) vaccine. Vaccine 23:2121-2131.
43. De Silva, O., Basketter, D. A., Barratt, M. D., Corsini, E., Cronin, M. T. D., Das, P. K., Degwert, J., Enk, A., Garrigue, J. L., Hauser, C., Kimber, I., Lepoittevin, J-P., Peguet, J., and Ponec, M. 1996. Alternative methods for skin sensitisation testing. The report and recommendations of the ECVAM workshop 19. ATLA 24:683-705.
44. Devauchelle, V., Marion, S., Cagnard, N., Mistou, S., Falgarone, G., Breban, M., Letourneur, F., Pitaval, A., Alibert, O., Lucchesi, C., Anract, P., Hamadouche, M., Ayral, X., Dougados, M., Gidrol, X., Fournier, C., and Chiocchia, G. 2004. DNA microarray allows molecular profiling of rheumatoid arthritis and identification of pathophysiological targets. Genes Immun. 5:597-608.
45. Dooley, M. A., and Hogan, S. L. 2003. Environmental epidemiology and risk factors for autoimmune disease. Curr. Opin. Rheumatol. 15:99-103.
46. Dragic, T., Litwin, V., Allaway, G. P., Martin, S. R., Huang, Y., Nagashima, K. A., Cavanan, C., Maddon, P. J., Koup, R. A., Moore, J. P., and Paxton, W. A. 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.
47. Edwards-Smith, C. J., Jonsson, J. R., Purdie, D. M., Sansal, A., Shorthouse, C., and Powell, E. E. 1999. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 30:526-530.
48. Encinas, J. A., and Kuchroo, V. K. 2000. Mapping and identification of autoimmunity genes. Curr. Opin. Immunol. 12:691-697.
49. Enk, A. H., and Katz, S. I. 1992. Early molecular events in the induction phase of contact sensitivity. Proc. Natl. Acad. Sci. USA 89:1398-1402.
50. Espinoza, J., Chaiworapongsa, T., Romero, R., Edwin, S., Rathnasabapathy, C., Gomez, R., Bujold, E., Camacho, N., Kim, Y. M., Hassan, S., Blackwell, S., Whitty, J., Berman, S., Redman, M., Yoon, B. H., and Sorokin, Y. 2003. Antimicrobial peptides in amniotic fluid: Defensins, calprotectin and bacterial/permeability-increasing protein in patients with microbial invasion of the amniotic cavity, intra-amniotic inflammation, preterm labor and premature rupture of membranes. J. Matern. Fetal Neonatal Med. 13:2-21.
51. Ezendam, J., Staedtler, F., Pennings, J., Vanderbriel, R. J., Pieters, R., Boffetta, P., Harlemen, J. H., and Vos, J. G. 2004. Toxicogenomics of subchronic hexachlorobenzene exposure in Brown Norway rats. Environ. Health Perspect. 112:782-791.
52. Fathman, C. G., Soares, L., Chan, S. M., and Utz, P. J. 2005. An array of possibilities for the study of autoimmunity. Nature 435:605-611.
53. Febbraio, M., Hajjar, D. P., and Silverstein, R. L. 2001. CD36: A class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Clin. Invest. 108:785-791.
54. Fellay, J., Marzolini, C., Meaden, E. R., Back, D. J., Buclin, T., Chave, J.-P., Decosterd, L. A., Furrer, H., Opravil, M., Pantaleo, G., Retelska, D., Ruiz, L., Schinkel, A. H., Vernazza, P., Eap, C. B., and Telenti, A. for the Swiss HIV Cohort Study. 2002. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study. The Lancet 359:30-36.
55. Ferraccioli, G. 2003. The possible clinical application of pharmacogenetics in rheumatology. J. Rheumatol. 30:2517-2520.
56. Fisher, M. T., Nagarkatti, M., and Nagarkatti, P. S. 2004. Combined screening of thymocytes using apoptosis-specific cDNA array and promoter analysis yields novel gene targets mediating TCDD-induced toxicity. Toxicol. Sci. 78:116-124.
57. Forrest, M. S., Lan, Q., Hubbard, A. E., Zhang, L., Vermeulen, R., Zhao, X., Li, G., Wu, Y. Y., Shen. M., Yin, S., Chanock, S. J., Rothman, N., and Smith, M. T. 2005. Discovery of novel biomarkers by microarray analysis of peripheral blood mononuclear cell gene expression in benzene-exposed workers. Environ. Health Perspect. 113:801-807.
58. Foster, W. R., Ladics, G. S., and Glatt, C. M. 2004. Validation of a minimal transcript biomarker set to differentiate between sensitizers and irritants in the local lymph node assay. Toxicol. Sci. 78(S-1):A208.
59. Friedman, H., Klwin, T. W., Newton, C., and Daaka, Y. 1995. Marijuana, receptors and immunomodulation. Adv. Exp. Med. Biol. 373:103-113.
60. Galvani, A. P., and Novembre, J. 2005. The evolutionary history of the CCR5-?32 HIV-resistance mutation. Microbes Infect. 7:302-309.
61. Geliebter, J., Mittelman, A., and Tiwari, R. K. 2003. Molecular phenotyping of the immune system by microarray analysis. Cancer Invest. 21:293-303.
62. Genin, P., Morin, P., and Civas, A. 2003. Impairment of interferon-induced IRF-7 gene expression due to inhibition of ISGF3 formation by trichostatin A. J. Virol. 77:7113-7119.
63. Germolec, D. R. 2004. Sensitivity and predictivity in immunotoxicity testing: Immune endpoints and disease resistance. Toxicol. Lett. 149:109-114.
64. Gildea, L. A., Ryan, C. A., Hulette, B. C., Dearman, R. J., Kimber, I., and Gerberick, G. F. 2004. Transcript profiling of T lymphocytes and dendritic cells in a co-culture system using anti-CD3 and allergen activation. J. Toxicol. Cut. Ocular Toxicol. 23:277-292.
65. Girardin, S. E., Boneca, I. G., Viala, J., Chamaillard, M., Labigns, A., Thomas, G., Philpott, D., and Samsonetti, P. J. 2003. Nod2 is a general sesor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278:8869-8872.
66. Glatt, C. M., Smith, C., Foster, W., and Ladics, G. S. 2003. Differentiation between sensitizers and irritants in the local lymph node assay using a minimal transcript set. Toxicol. Sci. 72(S-1):A1285.
67. Grabbe, S., and Schwarz, T. 1998. Immunoregulatory mechanisms involved in the elicitation of allergic contact hypersensitivity. Immunol. Today 19:37-44.
68. Graham, K. L., Robinson, W. H., Steinman, L., and Utz, P. J. 2004. High-throughput methods for measuring autoantibodies in systemic lupus erythematosus and other autoimmune diseases. Autoimmunity 37:269-272.
69. Greenhalgh, C. J., Metcalf, D., Thaus, A.L., Corbin, J.E., Uren, R., Morgan, P. O., Fabri, L. J., Zhang, H. G., Martin, H. M., Willson, T. A., Billestrup, N., Nicola, N. A., Baca, M., Alexander, W. S., and Hilton, D. J. 2002. Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J. Biol. Chem. 277:40181-40184.
70. Hayden, M. S. 2002. Pharmacogenomics and infectious diseases: Impact on drug response and applications to disease management. Am. H. Health - Syst. Pharm. 59:1626-1631.
71. Heller, R. A., Schena, M., Chai, A., Shalon, D., Bedilion, T., Gilmore, J., Woolley, D. E., and Davis, R. W. 1997. Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proc. Natl. Acad. Sci. USA 94:2150-2155.
72. Hjelmervik, T. O., Petersen, K., Jonassen, I., Jonsson, R., and Bolstad, A. I. 2005. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum. 52:1534-1544.
73. Hosford, D. A., Lai, E. H., Riley, J. H., Xu, C. F., Danoff, T. M., and Roses, A. D. 2004. Pharmacogenetics to predict drug-related adverse events. Toxicol. Pathol. 32 (Suppl) 1:9-12.
74. Hulette, B. C., Ryan, C. A., and Gerberick, G. F. 2002. Elucidating changes in surface marker expression of dendritic cells following chemical allergen treatment. Toxicol. Appl. Pharmacol. 182:226-233.
75. Hung, S. I., Chung, W. H., Liou, L. B., Chu, C. C., Lin, M., Huang, H. P., Lin, Y. L., Lan, J. L., yang, L. C., Hong, H. S., Chen, M. J., Lai P. C., Wu, M. S., chu, C. Yl, Wang, K. H., Chen, C. H., Fann, C. S., Wu, J. Y., and Chen, Y. T. 2005. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. USA. 102:4134-4139.
76. Hutton, J. J., Jegga, A. G., kong, S., Gupta, A., Ebert, C., Williams, S., Katz, J. D., and Aronow, B. J. 2004. microarray and comparative genomics-based identification of genes and gene regulatory regions of the nouse immune system. BMC Genomics 5:82-97.
77. Inohara, N., Ogura, Y., Fontalba, A., Guttierez, O., Pons, F., Crespo, J., Fukase, K., Inamura, S., Kusumoto, S., Hashimoto, M., foster, S. J., Moran, A. P., Fernandez-Luna, J. L., and Nunez, G. 2003. host recognition of bacterial muramyl dipeptide is mediatd throughNOD2: Impoications for Crohn's disease. J. Biol. Chem. 278:5509-5512.
78. Kamoi, H., Kanazawa, H., Hirata, K., Kurihara, N., Yano, Y., and Otani, S. 1995. Adrenomedullin inhibits the secretion of cytokine-induced neutrophil chemoattractant, a member of the interleukin-8 family, from rat alveolar macrophages. Biochem. Biophys. Res. Commun. 211:1031-1035.
79. Kaplowitz, N. 2004. Drug-induced liver injury. Clin. Infect. Dis. 38(Suppl. 2):S44-S48.
80. Kaplowitz, N. 2005. Idiosyncratic drug hepatotoxicity. Nature Rev. (Drug Discovery) 4:489-199.
81. Kimber, I., Basketter, D. A., Butler, M., Gamer, A., Garrigue, J-L., Gerberick, G. F., Newsome, C., Steiling, W., and Vohr, H-W. 2003. Classification of contact allergens according to potency: Proposals. Fd. Chem. Toxic. 41:1799-1809.
82. Kimber, I., Basketter, D. A., Gerberick, G. F., and Dearman, R. J. 2002. Allergic contact dermatitis. Int. Immunopharmacol. 2:201-211.
83. Kimber, I., and Cumberbatch, M. 1992. Dendritic cells and cutaneous immune responses to chemical allergens. Toxicol. Appl. Pharmacol. 117:137-146.
84. Kimber, I., Cumberbatch, M., Betts, C. J., and Dearman, R. J. 2004. Dendritic cells and skin sensitisation hazard assessment. Toxic. In Vitro 18:195-202.
85. Kimber, I., Cumberbatch., Dearman, R. J., Bhushan, M., and Griffiths, C. E. M. 2000. Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization. Br. J. Dermatol. 142:401-112.
86. Kimber, I., and Dearman, R. J. 2002. Allergic contact dermatitis: The cellular effectors. Contact Derm. 46:1-5.
87. Kimber, I., Dearman, R. J., Cumberbatch, M., and Huby, R. J. D. 1998. Langerhans cells and chemical allergy. Curr. Opinion Immunol. 10:614-619.
88. Kimber, I., Pichowski, J. S., Betts, C. J., Cumberbatch, M., Basketter, D. A., and Dearman, R. J. 2001. Alternative approaches to the identification and characterization of chemical allergens. Toxic. In Vitro 15:307-312.
89. Kinser, S., Jia, Q., Li, M., Laughter, A., Cornwell, P., Corton, J. C., and Pestka, J. 2004. Gene expression profiling in spleens of deoxynivalenol-exposed mice: Immediate early genes as primary targets. J. Toxicol. Environ. Health A 67:1423-1441
90. Klein, T. W., Newton, C., Zhu, W., Daaka, Y., and Friedman, H. 1995. Δ9-Tetrahydrocannabinol, cytokines, and immunity to Legionella pneumophila. Proc. Soc. Exp. Biol. Med. 209:205-212.
91. Klein, T. W., Lane, B., Newton, C. A., and Friedman, H. 2000. The cannabinoid system and cytokine network. Proc. Soc. Exp. Biol. Med. 225:1-8.
92. Krenn, V., Petersen, I., Haupl T., Koepenik, A., Blind, C., Dietel, M., Konthur, Z., and Skriner, K. 2004. Array technology and proteomics in autoimmune diseases. Pathol. Res. Pract 200:95-103.
93. Lard, L. R., van Gaalen, F. A., Schonkeren, J. J., Pieterman, E. J., Stoeken, G., Vos, K., Nelissen, R. G., Westendorp, R. G., Hoeben, R. C., Breedveld, F. C., Toes, R. E., and Huizinga, T. W. 2003. Association of the -2849 interleukin-10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis. Arthritis Rheum. 48:1841-1848.
94. Laughter, A. R., Dunn, C. S., Swanson, C. L. Howroyd, P., Cattley, R. C., and Corton, J. D. 2004. Role of the peroxisome proliferators-activated receptor alpha (PPARalpha) in responses to trichloroethylene and metabolites, trichloroacetate and dichloroacetate in mouse liver. Toxicology 203:83-98.
95. Liu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R., MacDonald, M. E., Stuhlmann, H., Koup, R. A., and Landau, N. R. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-377.
96. Lock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., Langer-Gould, A., Strober, S., Cannella, B., Allard, J., Klonowski, P., Austin, A., Lad, N., Kaminski, N., Galli, S. J., Oksenberg, J. R., Raine, C. S., Heller, R., and Steinman, L. 2002. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8:500-508.
97. Luster, M. I., Portier, C., Pait, D. G., Rosenthal, G. J., Germolec, D. R., Corsini, E., Blaylock, B. L., Pollock, P., Kouchi, Y., Craig, W., White, K. L., Munson, A. E., and Comment, C. E. 1993. Risk assessment in immunotoxicology. II. Relationships between immune and host resistance tests. Fundam. Appl. Toxicol. 21:71-82.
98. Luyendyk, J. P., Mattes, W. B., Burgoon, L. D., Zacharewski, T. R., Maddox, J. F., Cosma, G. N., Ganey, P. E., and Roth, R. A. 2004. Gene expression analysis points to hemostasis in livers of rats cotreated with lipopolysaccharide and ranitidine. Toxicol. Sci. 80:203-213.
99. Luzina, I. G., Atamas, S. P., Wise, R., Wigley, F. M., Xiao, H. Q., and White, B. 2002. Gene expression in bronchoalveolar lavage cells from scleroderma patients. Am. J. Respir. Cell. Mol. Biol. 26:549-557.
100. Maas, K., Chan, S., Parker, J., Slater, A., Moore, J., Olsen, N., and Aune, T. M. 2002. Cutting edge: Molecular portrait of human autoimmune disease. J. Immunol. 169:5-9.
101. Maecker, B., von Bergwelt-Baildon, Anderson, K. S., Vonderheide, R. H., and Schultze, J. L. 2001. Linking genomics to immunotherapy by reverse immunology - 'immunomics' in the new millennium. Curr. Mol. Med. 1:609-619.
102. Mahler, M., Kessenbrock, K., Raats, J., Williams, R., Fritzler, M. J., and Bluthner, M. 2003. Characterization of the human autoimmune response to the major C-terminal epitope of the ribosomal P proteins. J. Mol. Med. 81:194-204.
103. Martin, A. M., Nolan, D., Gaudieri, S., Almeida, C. A., Nolan, R., James, I., Carvalho, F., Phillips, E., Christiansen, F. T., Purcell, A. W., McCluskey, J., and Mallal, S. 2004. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl. Acad. Sci. USA. 101:4180-4185.
104. Martin, A. M., Nolan, D., James, I., Cameron, P. Leller, J., Moore, C., Phillips, E., Christiansen, F. T., and Mallal, S. 2005. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 19:9-99.
105. Martin, W., Sbai, H., and De Groot, A. S. 2003. Bioinformatics tools for identifying class I-restricted epitopes. Methods 29:289-298.
106. Mattes, W. B., Pettit, S. D., Sansone, S.-A., Bushel, P. R., and Waters, M. D. 2004. Database development in toxicogenomics: Issues and efforts. Environ. Health Perspect. 112(4):495-505.
107. McDonald, H. R., Bommhardt, U., and Cerrottini, J. C. 1995. Developmentally regulated expression of P-glycoprotein (multidrug resistance) activity in mouse thymocytes. Eur. J. Immunol. 25:1457-1460.
108. McKallip, R. J., Lombard, C., Fisher, M., Martin, B. R., Ryu, S., Grant, S., Nagarkatti, M., and Nagarkatti, P.S. 2002. Targeting CB2 cannabinoid receptors as a noveltherapty to treat malignant lymphblastic disease. Blood 100:627-634.
109. McKallip, R. J., Nagarkatti, M., and Nagarkatti, P. S. 2005. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J. Immunol. 174:3281-3289.
110. Metcalf, D., Greenhalgh, C. J., Viney, E., Willson, T. A., Starr, R., Nicola, N. A., Hilton, D. J., and Alexander, W. S. 2000. Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 405:1069-1073.
111. Mocellin, S., Wang, E., Panelli, M., Pilati, P., Marincola, F. M. 2004. DNA array-based gene profiling in tumor immunology. Clin. Cancer Res. 10:4597-1606.
112. Morahan, G., and Morel, L. 2002. Genetics of autoimmune diseases in humans and in animal models. Curr. Opin. Immunol. 14:803-811.
113. Mosca, P. J., Lyerly, H. K., Ching, C. D., Hobeika, A. C., Clay, T. M., and Morse, M. A. 2003. Proteomics for monitoring immune responses to cancer vaccines. Curr. Opin. Molec. Therap. 5:39-43.
114. Nau, G. J., Richmond, J. F., Schlesinger, A., Jennings, E. G., Lander, E. S., and Young, R. A. 2002. Human macrophage activation programs induced by bacterial pathogens. Proc. Natl. Acad. Sci. USA. 99:1503-1508.
115. Ng, B., Yang, F., Huston, D. P., Yan, Y., Yang, Y., Xiong, Z., Peterson, L. E., Wang, H., and Yang, X. F. 2004. Increased noncanonical splicing of autoantigen transcripts provides the structural basis for expression of untolerized epitopes. J. Allergy Clin. Immunol. 114:1463-1470.
116. Oestreicher, J. L., Walters, I. B., Kikuchi, T., Gilleaudeau, P., Surette, J., Schwertschlag, U., Dorner, A. J., Krueger, J. G., and Trepicchio, W. L. 2001. Molecular classification of psoriasis disease-associated genes through pharmacogenomics expression profiling. Pharmacogenomics J. 1:272-287.
117. Padyukov, L., Hytonen, A. M., Smolnikova, M., Hahn-Zoric, M., Nilsson, N., Hanson, L. A., Tarkowski, A., and Klareskog, L. 2004. Polymorphism in promoter region of IL10 gene is associated with rheumatoid arthritis in women. J. Rheumatol. 31:422-425.
118. Patterson, R. M., Walker, N., Baker, S., Dickinson, T., White, K., Musgrove, D., Harrsion, S., and Germolec, D. R. Gene expression alterations in immune system pathways following exposure to immunosuppressive chemicals. The Toxicologist 2005 March: 73.
119. Paxton, W. A. and Kang, S. 1998. Chemokine receptor allelic polymorphisms: relationships to HIV resistance and disease progression. Seminars Immunol. 10:187-194.
120. Pennie, W. D., and Kimber, I. 2002. Toxicogenomics: Transcript profiling and potential application to chemical allergy. Toxicol. In Vitro 16:319-326.
121. Peters, S. P. 2004. Asthma treatment in the 21st century - what's next? Clin. Rev. Allergy Immunol. 27:197-205.
122. Phillips, E. J., Wong, G. A., Kaul, R., Shahabi, K., Nolan, D. A., Knowles, S. R., Martin, A. M., Mallal, S. A., and Shear, N. H. 2005. AIDS 10:979-981.
123. Pichowski, J. S., Cumberbatch, M., Dearman, R. J., Basketter, D. A., and Kimber I. 2000. Investigation of induced changes in interleukin 1β m RNA expression by cultured human dendritic cells as an in vitro approach to skin sensitization testing. Toxicol. In Vitro 14:351-360.
124. Pichowski, J. S., Cumberbatch, M., Dearman, R. J., Basketter, D. A., and Kimber, I. 2001. Allergen-induced changes in interleukin 1β (IL-1β) mRNA expression by human blood-derived dendritic cells: Inter-individual differences and relevance for sensitization testing. J. Appl. Toxicol. 21:115-121.
125. Pirmohamed, M., and Back, D. J. 2001. The pharmacogenomics of HIV therapy. Pharmacogenomics J. 1:243-253.
126. Pruett, S. B., Schwab, C., Zheng, Q., and Fan, R. 2004. Suppression of innate immunity by acute ethanol administration: A global perspective and a new mechanism beginning with inhibition of signaling through toll-like receptor 3. J. Immunol. 173:2715-2724.
127. Pulendran, B. 2005. Variegation of the immune response with dendritic cells and pathogen recognition receptors. J. Immunol. 174:2457-2465.
128. Reutter, K., Jager, D., Degwert, J., and Hoppe, U. 1997. In vitro model for contact sensitization. II Induction of IL-1β mRNA in human blood-derived dendritic cells by contact sensitizers. Toxicol. In Vitro 11:619-626.
129. Reveille, J. D. 2005. Genetic studies in the rheumatic diseases: Present status and implications for the future. J. Rheumatol. Suppl. 72:10-13.
130. Robinson, W. H., DiGennaro, C., Hueber, W., Haab, B. B., Kamachi, M., Dean, E. J., Fournel, S., Fong, D., Genovese, M. C., de Vegvar, H. E., Skriner, K., Hirschberg, D. L., Morris, R. I., Muller, S., Pruijn, G. J., van Venrooij, W. J., Smolen, J. S., Brown, P. O., Steinman, L., and Utz, P. J. 2002a. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat. Med. 8:295-301.
131. Robinson, W. H., Garren, H., Utz, P. J., and Steinman, L. 2002b. Proteomics for the development of DNA tolerizing vacines to treat autoimmune disease. Clin. Immunol. 103:7-12.
132. Robinson, W. H., Steinman, L., and Utz, P. J. 2003. Protein arrays for autoantibody profiling and fine-specificity mapping. Proteomics 3:2077-2084.
133. Romani, N., Gruner, S., Brang, D., Lampgen, E., Lenz, A., Trockenbacher, B., Konwalinka, G., Fritsch, P. O., Steinman, R. M., and Schuler, G. 1994. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180:83-93.
134. Roth, M. D., Baldwin, G. C., and Tashkin, D. P. 2002. Effects of delta-9-tetrahydrocannabinol on human immune function and host defense. Chem. Phys. Lipids. 121:229-239.
135. Rus, V., Atamas, S. P., Shustova, V., Luzina, I. G., Selaru, F., Magder, L. S., and Via, C. S. 2002. Expression of cytokine- and chemokine-related genes in peripheral blood mononuclear cells from lupus patients by cDNA array. Clin. Immunol. 102:283-290.
136. Ryan, C. A., Hulette, B. C., and Gerberick, G. F. 2001. Approaches for the development of cell-based in vitro methods for contact sensitization. Toxic. In Vitro 15:43-55.
137. Ryan, C. A., Gildea, L. A., Hulette, B. C., Dearman, R. J., Kimber, I., and Gerberick, G. F. 2004a. Gene expression changes in peripheral blood-derived dendritic cells following exposure to a contact allergen. Toxicol. Lett. 150:301-316.
138. Ryan, C. A., Hulette, B. C., Gildea, L. A., Dearman, R. J., Kimber, I., and Gerberick, G. F. 2004b. Examination of phenotypic changes in peripheral blood-derived dendritic cells following exposure to a contact allergen: Cell surface marker and gene expression. J. Toxicol. Cut Ocular Toxicol. 23:91-104.
139. Ryan, C. A., Gerberick, G. F., Gildea, L. A., Hulette, B. C., Betts, C. J., Cumberbatch, M. C., Dearman, R. J., and Kimber, I. 2005. Interactions of contact allergens with dendritic cells: Opportunities and challenges for the development of novel approaches to hazard assessment. Toxicol. Sci. (in press).
140. Sallusto, F., and Lanzavecchia, A., 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony stimulating factor plus interleukin-4 and down-regulated by tumor necrosis factor α. J. Exp. Med. 179:1109-1118.
141. Sanchez, C., Galve-Roperh, I., Canova, C., Brachet, P. and Guzman, M. 1998. Δ9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett. 436:6-10.
142. Sanchez, C., de Ceballos, M. L., del Pulgar, T. g., Rueda, D., Corbacho, C., Velasco, G., Galve-Roperh, I., Huffman, J. W., Ramon, Y. C. S., and Guzman, M. 2001. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 61:5784-5789.
143. Selak, S., Chan, E. K., Schoenroth, L., Senecal, J. L., and Fritzler, M. J. 1999. Early endosome antigen. 1: An autoantigen associated with neurological diseases. J. Investig. Med. 47:311-318.
144. Selak, S., Mahler, M., Miyachi, K., Fritzler, M. L., and Fritzler, M. J. 2003. Identification of the B-cell epitopes of the early endosome antigen 1 (EEA1). Clin. Immunol. 109:154-164.
145. Selgrade, M. K. 1999. Use of immunotoxicity data in health risk assessments: Uncertainties and research to improve the process. Toxicology 133:59-72.
146. Sette, A., Fleri, W., Peters, B., Sathiamurthy, M., Bui, H. H., and Wilson, S. 2005. A roadmap for the immunomics of category A-C pathogens. Immunity 22:155-161.
147. Shaffer, A. L., Rosenwald, A., Hurt, E. M., Giltnane, J. M., Lam, L. E., Pickeral, O. K., and Staudt, L. M. 2001. Immunity 15:375-385.
148. Shen, N., and Tsao, B. P. 2004. Current advances in the human lupus genetics. Curr. Rheumatol. Rep. 6:391-398.
149. Smith, M. T., Vermeulen, R., Li, G., Zhang, L., Lan, Q., Hubbard, A. E., Forrest, M. S., McHale, C., Zhao, X., Gunn, L., Shen, M., Rappaport, S. M., Yin, S., Chanock, S., and Rothman, N. 2005. Use of 'omic' technologies to study humans exposed to benzene. Chem. Biol. Interact. 153-154:123-127.
150. Sharova, L. V., Gogal, Jr., R. M., Sharov, A. A., Chrisman, M. V., and Holladay, S. D. 2002. Immune stimulation in urethane-exposed pregnant mice increases expression level of spleen leukocyte genes for TGFbeta3 GM-CSF and other cytokines that may play a role in reduced chemical-induced birth defects. Int. Immunopharmacol. 2:1477-1489.
151. Sharova, L. V., Sharov, A. A., Sura, P., Gogal, Jr., R. M., Smith, B. J., and Holladay, S. D. 2002. Maternal immune stimulation reduces both placental morphologic damage and down-regulated placental growth-factor and cell cycle gene expression caused by urethane: Are these events related to reduced teratogenesis? Int. Immunopharmacol. 3:945-955.
152. Staudt, L. M., and Brown, P. O. 2000. Genomic views of the immune system. Annu. Rev. Immunol. 18:829-859.
153. Tedder, T. F., and Engel, P. 1994. CD20: A regulator of cell-cycle progression of B lymphocytes. Immunol. Today 15:450-454.
154. Tuschl, H., and Kovac, R. 2001. Langerhans cells and immature dendritic cells as model systems for screening skin sensitizers. Toxicol. In Vitro 15:327-331.
155. Tsuchl, H., Kovac, R., and Weber, E. 2000. The expression of surface markers on dendritic cells as indicators for the sensitizing potential of chemicals. Toxicol. In Vitro 14:541-549.
156. Utrecht, J. 2001. Prediction of a new drug's potential to cause idiosyncratic reactions. Curr. Opin. Drug Disc. Dev. 4:55-59.
157. Utrecht, J. 2003. Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. Drug Disc. Today 8:832-837.
158. van der Pouw Kraan, T. C., van Gaalen, F. A., Huizinga, T. W., Pieterman, E., Breedveld, F. C., and Verweij, C. L. 2003. Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: Evidence for the existence of multiple pathways of tissue destruction and repair. Genes Immun. 4:187-196.
159. van der Pouw Kraan, T. C., Kasperkovitz, P. V., Verbeet, N., and Verweij, C. L. 2004. Genomics in the immune system. Clin. Immunol. 111:175-185.
160. Wang, Z., Neuburg, D., Li, C., Su, L., Kim, J. Y., Chen, J. C., and Christiani, D. C. 2005. Global gene expression profiling in whole-blood samples from individuals exposed to metal fumes. Environ. Health Perspect. 113:233-241.
161. Wu, M. M., Chiou, H. Y., Ho, I. C., Chen, C. J., Lee, T. C. 2003. Gene expression of inflammatory molecules in circulating lymphocytes from arsenic-exposed human subjects. Environ. Health Perspect. 111:1429-1438.
162. Wu, R., Zhou, M., and Wang, P. 2003. Adrenomedullin and adrenomedullin binding protein-1 downregulate TNF-alpha in macrophage cell line and rat Kupffer cells. Regul. Pept. 112:19-26.
163. Zhou, X., Tan, F. K., Xiong, M., Milewicz, D. M., Feghali, C. A., Fritzler, M. J., Reveille, J. D., and Arnett, F. C. 2001. Systemic sclerosis (scleroderma): Specific autoantigen genes are selectively overexpressed in scleroderma fibroblasts. J. Immunol. 167:7126-7133.
164. Zhu, M., John, S., Berg, M., and Leonard, W. J. 1999. Functional association of Nmi with Stat5 and Statl in IL-2- and IFNgamma-mediated signaling. Cell 96:121-130.